Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
2021 Year in Review - Multiple Myeloma
Multiple Myeloma
Results of the Phase 3 GMMG-HD7 Trial of Isatuximab plus Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Transplant-Eligible NDMM
Read More
Multiple Myeloma
International Myeloma Working Group Recommendations for the Treatment of Patients with RRMM
Read More
Multiple Myeloma
Longer-Term Outcomes with Single-Agent Belantamab Mafodotin in Patients with RRMM: 13-Month Follow-Up from the Pivotal DREAMM-2 Study
Read More
Multiple Myeloma
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd), Autologous Transplantation, and MRD Response–Adapted Treatment Modification in NDMM
Read More
Multiple Myeloma
Updated Results from the CARTITUDE-1 Study of Ciltacabtagene Autoleucel CAR T-Cell Therapy in RRMM
Read More
Multiple Myeloma
Updated Analysis of the GRIFFIN Trial of Daratumumab plus RVd in Transplant-Eligible NDMM
Read More
1
2
3
Page 3 of 3
Results 21 - 26 of 26